Investor Relations

Investor Relations

NYSE American Symbol SYN
Price
Change
Volume
Day Low/High
52 Week Low/High

Analyst Coverage

William Blair & Co.Y. Katherine Xu, Ph.D.

BTIGTimothy Chiang

Griffin SecuritiesKeith A. Markey, Ph.D., M.B.A.

Overview

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).

View Profile

Leadership

Our experienced management team holds an extensive clinical and commercial track record.

Investor Relations

Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
info@syntheticbiologics.com

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
#430
Denver, CO 80209
T: (303) 282-4800